Statins for Health & Longevity - Quick Reference Sheet
evipedia.aidev
← Back

Statins for Health & Longevity

Created on 08/23/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Statins are prescription medicines that lower cholesterol-carrying particles in the blood. Trial evidence shows fewer heart attacks, clot-type strokes, and heart-related deaths, especially after a first heart attack or stroke and when starting particle levels are high. They are an artery-protection tool, not a general vitality medicine. Costs include a small blood-sugar rise and muscle symptoms. (Full Review)

Protocol

Conventional cardiology
Atorvastatin 40–80 mg or rosuvastatin 20–40 mg
High-intensity after clinical atherosclerotic disease or LDL cholesterol of 190 mg/dL or higher; moderate intensity for many primary-prevention adults
Prevention-oriented (Attia/Dayspring-type)
Apolipoprotein B as the treatment target
Often rosuvastatin or pitavastatin, add-on ezetimibe, and sometimes a PCSK9 inhibitor, aiming well below conventional LDL cutoffs
Time of day
Evening for short-half-life agents
Simvastatin and lovastatin typically in the evening; atorvastatin and rosuvastatin any time
Time to effect
Absolute benefit
Years
Accrues with years of lower particle exposure
Event curves
About 1 year
Event curves typically separate; fewer heart attacks, clot-type strokes, and cardiovascular deaths
LDL cholesterol and apolipoprotein B
4–6 weeks
Particle numbers fall within this window

Benefits

Contraindications
  • Pregnancy, except rare very-high inherited-risk cases under 2021 labeling
  • Breastfeeding
  • Decompensated cirrhosis or Child-Pugh Class C liver disease (the most severe liver-failure category)
  • Unexplained persistent liver enzymes more than three times the upper limit of normal
  • Active rhabdomyolysis or immune-mediated necrotizing myopathy with anti-HMGCR antibodies
  • Documented severe hypersensitivity to the specific agent
  • Concurrent gemfibrozil, especially with simvastatin at any high dose
    •
Key Interactions
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) with simvastatin, lovastatin, and atorvastatin (caution to contraindication at high simvastatin doses)
  • Cyclosporine and some other transplant drugs (many labels contraindicate or cap the dose)
  • Colchicine
  • Warfarin (simvastatin, rosuvastatin, or fluvastatin)
  • High-dose niacin and red yeast rice (caution to contraindication)
  • Diltiazem, verapamil, amiodarone (simvastatin dose caps)
  • St. John's wort (simvastatin, atorvastatin)
  • Over-the-counter (OTC) cimetidine and topical/oral azole antifungals (ketoconazole, clotrimazole) with simvastatin and lovastatin
  • Additive LDL-lowering (ezetimibe; PCSK9 inhibitors (evolocumab, alirocumab); bempedoic acid; plant sterols)
    •

Risk & Side Effects

  • High: Muscle symptoms, including muscle breakdown; new-onset type 2 diabetes and a rise in blood sugar; liver enzyme elevations; kidney function changes; rise in lipoprotein(a)
    •
  • Medium: Hemorrhagic stroke risk after prior stroke
    •
  • Low: Cognitive symptoms; cataracts; immune-mediated necrotizing myopathy
    •
  • Speculative: Lasting mitochondrial injury
    •

Monitoring

Marker Target Why
Apolipoprotein B 20–60 mg/dL for aggressive prevention; many clinics use <80 Particle number that enters artery walls
LDL cholesterol <70 mg/dL high-risk; <55 mg/dL very-high-risk Common surrogate for apolipoprotein B
Lipoprotein(a) <30 mg/dL or <75 nmol/L Inherited residual particle risk; statins can raise it
High-sensitivity C-reactive protein <0.5–1.0 mg/L Residual inflammatory risk on treatment
Hemoglobin A1c <5.3–5.5% Detect the statin-associated glucose shift
Fasting insulin <5–8 μIU/mL Early insulin resistance before hemoglobin A1c moves
Alanine aminotransferase Near personal baseline; generally <30–40 U/L Liver-enzyme signal
Creatine kinase Personal baseline; investigate symptoms plus a large rise Muscle injury
Thyroid-stimulating hormone About 0.5–2.5 mIU/L in functional practice Hypothyroidism raises LDL and mimics myalgia
Fasting glucose Pair with fasting insulin Glucose reserve and the diabetes shift
Coronary artery calcium scan When it would change intensity Whether plaque is already present

Cadence: Baseline before the first dose; 6–8 weeks (lipids, apolipoprotein B, enzymes, glucose); 3–6 months; then every 6–12 months if stable; sooner after dose changes or new muscle symptoms

Qualitative Assessment

  • Energy and training load compared with the pre-statin baseline
  • Unexplained muscle soreness, cramps, or weakness, especially if present at rest
  • Subjective cognitive clarity and sleep quality after evening doses
  • New thirst, nocturia (waking at night to urinate), or other glucose-related symptoms
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.